Le rapport
Actualités vérifiées sur le financement, les sièges sociaux et les dirigeants des entreprises les plus innovantes au monde
200 rapports et plus encore
Expedition Therapeutics Raises $115M Series B for Oral DPP1 Inhibitor for COPD
Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.
Expedition Therapeutics raises $165M Series A at $700M valuation
Expedition Therapeutics raises $165M in Series A at $700M valuation. Developer of therapies for inflammatory and respiratory diseases...
Expedition Therapeutics Raises $165M in Series A
Expedition Therapeutics, a Biotech company based in San Francisco, CA, has raised $165M in Series A at a $650M valuation led by Sofinnova Investments, Novo Holdings.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Expedition Therapeutics raises $165M Series B at $850M valuation
Expedition Therapeutics raises $165M in Series B at $850M valuation. Developing novel therapeutics for cardiometabolic diseases...
Affichage de 9 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.